Equinox is structured around developsment of innovative solutions and treatments designed to enable better management for glaucoma patients through understanding, measuring, and controlling the balance of eye and brain pressures. Effectively, the firm is addressing radically changing treatment of glaucoma and other progressive eye diseases - pioneering a new understanding of glaucoma based on deep exploration into the physics of the eye and eye pressure. With funding from Flying-L-Partners, Visionary Ventures and Blue Stem, Equinox has been establishing a new paradigm in glaucoma care for physicians and patients through a revolutionary approach to treatment and management known as Multi-Pressure Glaucoma Management (MGM).
